BEIJING, Feb. 26, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials. The Company completed patient enrollment of a Phase III registrational clinical trial of BCL2 inhibitor mesutoclax (ICP-248) in combination with BTK inhibitor orelabrutinib for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. Mesutoclax is a novel, highly selective oral BCL2 inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity...

New office strengthens global engineering capabilities to scale intelligent AI agents worldwide SANTA CLARA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice and conversational AI, today announced the opening of its new state-of-the-art innovation hub in Bengaluru, India. The expansion marks a significant milestone in the company’s evolution to scale agentic AI globally, positioning SoundHound at the epicenter of India’s rapidly accelerating AI economy. The opening coincides with a period of historic momentum for the Indian technology sector. As the country reinforces its role as a global AI powerhouse, SoundHound’s new Bengaluru hub will serve as a critical engine for the company’s next wave of innovation, including continued advancement of its next generation agentic AI platform. SoundHound...

Saskatoon, SK., Feb. 25, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning developer of drone solutions, software, and robotics, today announced the pricing of a registered direct offering to purchase 7,150,000 common shares (or pre-funded warrants in lieu thereof) of the Company (each, a “Common Share” or “Pre-Funded Warrant”), at a price of US$7.00, for gross proceeds of approximately US$50.0 million, before deducting placement agent discounts and offering expenses (the “Offering”). Maxim Group LLC is acting as lead placement agent for the Offering. Raymond James Ltd. and Ladenburg Thalmann & Co. Inc. are acting as co-placement agents for the offering. Draganfly currently intends to use the net proceeds from the Offering for general corporate purposes,...

NEW YORK, NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) — TRG Latin America Acquisitions Corp. (“TRG” or the “Company”) announced today that it priced its initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Stock Exchange (“Nasdaq”) and trade under the ticker symbol “TRGSU” beginning February 26, 2026. Each unit consists of one Class A ordinary share and one right entitling the holder thereof to receive one-tenth of one Class A ordinary share upon the consummation of an initial business combination. The Class A ordinary shares and rights comprising the units are expected to begin separate trading no later than the 52nd day following this date. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on Nasdaq under...

WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the pricing of its upsized public offering of 1,600,000 shares of its common stock at a price to the public of $125.00 per share. In addition, Palvella has granted the underwriters a 30-day option to purchase up to an additional 240,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Palvella from this offering are expected to be $200 million, before deducting...

New York, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) —  APEX Tech Acquisition Inc., a blank check company incorporated in the Cayman Islands as an exempted company (the “Company”), today announced the pricing of its initial public offering (“IPO”) of 10,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one ordinary share and one right to receive one-fourth (1/4) of one ordinary share upon the consummation of an initial business combination. The units are expected to trade on The New York Stock Exchange (“NYSE”) under the ticker symbol “TRADU” beginning February 26, 2026. The Company expects the IPO to close on February 27, 2026, subject to customary closing conditions. Once the securities comprising the units begin separate trading, the ordinary shares and the rights are expected to be traded on...